Cargando…

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study

BACKGROUND: Hypomethylating agents (HMA) are considered the first-line therapy for high-risk myelodysplastic syndromes (MDS). However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs. decitabine (DAC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Naibo, Qin, Tiejun, Du, Xiaoyan, Wang, Bingyi, Wang, Xiaoyun, Xu, Zefeng, Pan, Lijuan, Qu, Shiqiang, Xiao, Zhijian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856837/ https://www.ncbi.nlm.nih.gov/pubmed/33514682 http://dx.doi.org/10.12659/MSM.928454

Ejemplares similares

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy
por: Qu, Shiqiang, et al.
Publicado: (2023)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
por: Almasri, Jehad, et al.
Publicado: (2018)

A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes
por: Feng, Gege, et al.
Publicado: (2016)

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder
por: Huang, Huijun, et al.
Publicado: (2021)

ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant
por: Qu, Shiqiang, et al.
Publicado: (2022)

Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes
por: Wang, Jingya, et al.
Publicado: (2016)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms
por: Zhang, Yudi, et al.
Publicado: (2022)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R
por: Li, Bing, et al.
Publicado: (2016)

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
por: Huang, Huijun, et al.
Publicado: (2020)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine
por: Laribi, Kamel, et al.
Publicado: (2019)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine
por: Sato, Kazuya, et al.
Publicado: (2021)

Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis
por: Ma, Jiale, et al.
Publicado: (2021)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
por: Luo, Xueping, et al.
Publicado: (2018)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis
por: Frontiers Production Office,
Publicado: (2023)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine
por: Pawlak, Alicja, et al.
Publicado: (2022)

A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine
por: Kumode, Takahiro, et al.
Publicado: (2014)

Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
por: Lee, Byung-Hyun, et al.
Publicado: (2020)

Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors
por: Liu, Tangxia, et al.
Publicado: (2020)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
por: Garcia, Jacqueline S, et al.
Publicado: (2010)

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes
por: DING, KAI, et al.
Publicado: (2016)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
por: Wu, Depei, et al.
Publicado: (2015)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
por: Liu, Hui, et al.
Publicado: (2023)

Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis
por: Li, Xiao, et al.
Publicado: (2014)

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
por: McCormack, Steven E, et al.
Publicado: (2010)

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
por: Ritchie, Ellen K
Publicado: (2012)

Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations
por: Kim, Yoo-Jin, et al.
Publicado: (2013)

Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes
por: Kim, Kyuryung, et al.
Publicado: (2020)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aeo50401fmifmh1flnlhidoiee